Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0005684 (bladder cancer)
 16,431 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Krukenberg tumors described by Friedrich Ernst Krukenberg are still fascinating for their mysterious origin. It is known to be a rare entity and commonly originates from adenocarcinoma of stomach. We present three interestingly rare cases of this entity, revealed by 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (F-18 FDG-PET/CT) scan and discuss how F-18 FDG-PET/CT can prognosticate, alter the course of treatment in such patients. Ovarian metastatic deposits were detected in patients with renal cell, duodenal, and gall bladder carcinoma. Three visits were possible in patient with duodenal cancer (favorable response to therapy), two visits in renal cell cancer (progressive disease pattern) and only single visit for gall bladder cancer. Potentials of F-18 FDG-PET/CT scan for Krukenberg disease is still in exploratory phase, but it's applications in diagnosis, disease monitoring, therapeutic response monitoring, and prognosticating are unparalleled with other imaging modalities.
 ...
PMID:Krukenburg Tumors Arising from Rare Primary Sites: Role of 18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Management and Outcome. 3157 21

Purpose To assess the diagnostic accuracy of fluorine-18 fluorodeoxyglucose positron emission tomography combined with the computed tomography (18F-FDG PET/CT) in the detection of recurrent or residual urinary bladder cancer with meta-analysis. Methods We searched PubMed/MEDLINE, Embase, Web of Science, CBM, CNKI, VIP, and Wanfang databases through October 2019. Two reviewers independently screened the full articles. The imaging findings were confirmed by either histopathology or clinical follow-up. Sensitivity, specificity likelihood ratio and diagnostic odds ratio were pooled with 95 % confidence intervals (CI). Overall test performance was summarized by a summary receiver operating characteristic (ROC) curve. The Meta-DiSc software (version 1.4) was used to perform the meta-analysis. Results The meta-analysis included 7 studies. The pooled sensitivity and specificity of PET/CT for the detection of recurrent or residual urinary bladder cancer was 94.0% (95% CI: 91.0%-96.0%) and 92.0% (95% CI: 88.0%-95.0%), respectively. Positive likelihood ratio, negative likelihood ratio and diagnostic odds ratio were 9.77 (95% CI: 4.91-19.41), 0.99(95% CI: 0.06-0.13) and 95.09 (95% CI: 47.96-188.53), respectively. When residual urinary bladder cancer was excluded, sensitivity changed slightly. Conclusion This meta-analysis suggested that the diagnostic accuracy of PET/CT was good in detecting recurrent or residual urinary bladder cancer.
 ...
PMID:Diagnostic Evaluation of 18F-FDG PET/CT Imaging in Recurrent or Residual Urinary Bladder Cancer: A Meta-Analysis. 3230 63

Synchronous primary tumours along the urinary tract are not common. Preliminary assessment with FDG PET of patients with bladder cancer remains difficult due to intense accumulation of excreted FDG in urine. CT component helps to define the anatomical details and extent when ever other tumours are suspected.
 ...
PMID:A rare presentation of primary synchronous renal tract tumours on (18F)- fluorodeoxyglucose positron emission tomography- computed tomography. 3240 Jul 61

Bladder cancer (BC) is the most common cancer of the urinary tract in the United States. Imaging plays a significant role in the management of patients with BC, including the locoregional staging and evaluation for distant metastatic disease, which cannot be assessed at the time of cystoscopy and biopsy/resection. We aim to review the current role of cross-sectional and molecular imaging modalities for the staging and restaging of BC and the potential advantages and limitations of each imaging modality. CT is the most widely available and frequently utilized imaging modality for BC and demonstrates good performance for the detection of nodal and visceral metastatic disease. MRI offers potential value for the locoregional staging and evaluation of muscular invasion of BC, which is critically important for prognostication and treatment decision-making. FDG-PET/MRI is a novel hybrid imaging modality combining the advantages of both MRI and FDG-PET/CT in a single-setting comprehensive staging examination and may represent the future of BC imaging evaluation.
 ...
PMID:The Role of Imaging in Bladder Cancer Diagnosis and Staging. 3294 89

Bladder cancer is one of the most common malignancies of the urinary tract. Cutaneous metastasis of bladder carcinoma is extremely rare with a limited number of cases, resulting mainly from iatrogenic seeding. Here, we present scan findings of cutaneous metastasis in a known case of carcinoma urinary bladder. The 18F FDG PET/CT scan revealed FDG avid nodular thickening of the skin and sub-cutaneous tissue with ulcerations involving anterior pelvic wall, walls of the scrotum and the base of the penis. Histopathology confirmed the diagnosis of cutaneous and subcutaneous metastasis.
 ...
PMID:18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in the Evaluation of Unusual Cutaneous Manifestation of Carcinoma Urinary Bladder. 3308 87

Bladder cancer (BC) is the 10th most common cancer worldwide. Approximately one quarter of patients with BC have muscle-invasive disease (MIBC). Muscle-invasive disease carries a poor prognosis and choosing the optimal treatment option is critical to improve patients' outcomes. Ongoing research supports the role of 2-deoxy-2-(18F)fluoro-D-glucose positron emission tomography (18F-FDG PET) in guiding patient-specific management decisions throughout the course of MIBC. As an imaging modality, 18F-FDG PET is acquired simultaneously with either computed tomography (CT) or MRI to offer a hybrid approach combining anatomical and metabolic information that complement each other. At initial staging, 18F-FDG PET/CT enhances the detection of extravesical disease, particularly in patients classified as oligometastatic by conventional imaging. 18F-FDG PET/CT has value in monitoring response to neoadjuvant and systemic chemotherapy, as well as in localizing relapse after treatment. In the new era of immunotherapy, 18F-FDG PET/CT may also be useful to monitor treatment efficacy as well as to detect immune-related adverse events. With the advent of artificial intelligence techniques such as radiomics and deep learning, these hybrid medical images can be mined for quantitative data, providing incremental value over current standard-of-care clinical and biological data. This approach has the potential to produce a major paradigm shift toward data-driven precision medicine with the ultimate goal of personalized medicine. In this review, we highlight current literature reporting the role of 18F-FDG PET in supporting personalized management decisions for patients with MIBC. Specific topics reviewed include the incremental value of 18F-FDG PET in prognostication, pre-operative planning, response assessment, prediction of recurrence, and diagnosing drug toxicity.
 ...
PMID:The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma. 3311 95


<< Previous 1 2 3 4 5